Clinical Trial Update: Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia

View source ↗

Summary

AstraZeneca-sponsored epidemiological study on treatment approaches for AQP4-IgG positive neuromyelitis optica spectrum disorder in Russia has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Snippet

Sponsor: AstraZeneca | Conditions: Rare Diseases, Neuromyelitis Optica Spectrum Disorder (NMOSD) | Status: SUSPENDED